ERBB2 and neoplasm: BsAbs targeting HER2 and EGFR, key oncogenic drivers in multiple tumor types, may benefit from the lessons learned in antibody‐drug conjugates (ADCs) design to improve target selectivity and optimize therapeutic windows [16].